Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparumLSA1 and LSAP2 for Efficacy against Liver-Stage Malaria

Despite promising progress in malaria vaccine development in recent years, an efficacious subunit vaccine against Plasmodium falciparumremains to be licensed and deployed. Cell-mediated protection from liver-stage malaria relies on a sufficient number of antigen-specific T cells reaching the liver during the time that parasites are present. A single vaccine expressing two antigens could potentially increase both the size and breadth of the antigen-specific response while halving vaccine production costs.